Fasiglifam is a Selective and Orally Active GPR40 Agonist
Fasiglifam (TAK-875) acts as a novel, orally available, selective GPR40 agonist. TAK-875 (0.01-10 μM) produces a concentration-dependent increase in intracellular IP production in CHO-hGPR40, with EC50 of 0.072 μM. Fasiglifam…